Live
- 13 killed, 18 injured as landslides, flash floods hit Indonesia's North Sumatra province
- Israeli PM seeks additional delay of testimony in court for criminal trial
- JAIN International Residential School, Bengaluru jointly with The Sports School to announce India’s First Integrated Scholarship Future25
- Sale certificate issued in pursuance to a court's auction not required to be stamped: Supreme Court
- Andhra Pradesh: Jagan flays Chandrababu-led govt for neglect of education
- Sri Lanka issues flood warnings for 12 flood-prone river basin areas
- IPL 2025 Auction: Venkatesh Iyer sold to KKR for Rs 23.75 cr, Stoinis joins PBKS for Rs 11 crore
- Kharge to lead Opposition strategy meeting as Parliament session kicks off on Monday
- Three killed in firing as violence breaks out amid Sambhal mosque survey in UP
- IPL 2025 Auction: Ravichandran Ashwin, Rachin Ravindra return to Chennai Super Kings
Final phase of Covaxin clinical trials underway at NIMS
Final phase of Covaxin clinical trials underway at NIMS
Clinical trials of Covaxin, jointly developed by Bharat Biotech and ICMR have reached the final phase at Nizam's Institute of Medical Sciences (NIMS), Hyderabad.
Hyderabad: Clinical trials of Covaxin, jointly developed by Bharat Biotech and ICMR have reached the final phase at Nizam's Institute of Medical Sciences (NIMS), Hyderabad. Booster dose has been given to 10 volunteers today and to 11 volunteers on Tuesday.
According to the hospital authorities, the vaccine is said to have given better results in the second phase. In the first phase, 50 volunteers have been given Covaxin zero dose and the health condition of all is said to be stable. Out of the 50, people those who have completed their 14 days from the date of the first dose have been selected for the booster dose.
Those who received the booster dose will be doctor's observation for 24 hours before sending them to home. So far, seven persons have got booster dose in the second phase. The doctors said that they are speaking to the volunteers on video call twice a day. The condition of those who received the first shot and second shot is stable.
NIMS is one among 12 hospitals chose by the ICMR to conduct human trials of Covaxin. The vaccine was developed from a strain of SARS-CoV-2 isolated by ICMR-National Institute of Virology, Pune.
